Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $1.9 million.

  • Anika Therapeutics' Capital Expenditures rose 5518.09% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 945.93%. This contributed to the annual value of $7.7 million for FY2024, which is 4250.97% up from last year.
  • As of Q3 2025, Anika Therapeutics' Capital Expenditures stood at $1.9 million, which was up 5518.09% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Capital Expenditures ranged from a high of $3.4 million in Q2 2024 and a low of $570000.0 during Q1 2021
  • In the last 5 years, Anika Therapeutics' Capital Expenditures had a median value of $1.5 million in 2025 and averaged $1.7 million.
  • In the last 5 years, Anika Therapeutics' Capital Expenditures soared by 106864.86% in 2021 and then crashed by 5689.1% in 2025.
  • Anika Therapeutics' Capital Expenditures (Quarter) stood at $1.1 million in 2021, then soared by 124.4% to $2.5 million in 2022, then fell by 27.24% to $1.8 million in 2023, then dropped by 28.97% to $1.3 million in 2024, then soared by 44.38% to $1.9 million in 2025.
  • Its Capital Expenditures stands at $1.9 million for Q3 2025, versus $1.5 million for Q2 2025 and $2.8 million for Q1 2025.